We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.25 | 1.10 | 1.40 | 1.25 | 1.25 | 1.25 | 592,472 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -3.57 | 1.69M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/7/2020 08:35 | Yes your right seen it coming 4 or 5p soon | datait | |
23/7/2020 08:35 | Will move up again soonNews will be out soon typical mm's scaring a few ppl to sell | stoop | |
23/7/2020 08:34 | Early stages will take years to get a contract then someone else will be doing the same ????? | datait | |
23/7/2020 08:33 | you seem to be trapped on this thread, that's for sure | bountyhunter | |
23/7/2020 08:32 | Timbrrrrrrrrrrrrrrrr | datait | |
23/7/2020 08:31 | Trapped for years to come | datait | |
23/7/2020 08:30 | How low can you go how low can you go all the way to the floor mugs piled in ffs greed | datait | |
23/7/2020 08:28 | This will fall further yet no news for at least 3 weeks | datait | |
23/7/2020 08:26 | Fib retracements on a penny stock? lol | hodhasharon | |
23/7/2020 08:26 | 5p coming will hover over it hehehehehe | datait | |
23/7/2020 08:20 | No reason for stock to go further down.. as I explained we already did the classic 61.8% fib retracement yesterday...people selling today after yesterday's retracement will regret | montynj | |
23/7/2020 08:16 | From rns seems project will be around 120k to 200k max ,but this will be good step forward .sp may go down today but it's worth long term holding Dyor | tmmalik | |
23/7/2020 08:12 | The contract with large pharma hasn't disappeared....other contracts still to come...mkt cap of this co still far too low relative to peer group | montynj | |
23/7/2020 08:08 | This is brutal | r9505571 | |
23/7/2020 08:07 | A 61.8% fib retracement of rally from 16th July is 10.25p so we have retraced enough now...stock should find a new support around here | montynj | |
22/7/2020 19:21 | For those new to Physiomics The upcoming 'new Large Pharma' deal isn't the real story here. Even though it could spark a 'domino effect' with over 50+ potential clients talking to PYC [Domino effect might be pushing it with slow moving Big Pharma :-p ] Real story is in Personalised Oncology Precision Medicine where Physiomics' peers include companies like Tempus a $5 Billion start up ! The coming landgrab phase in growth of that market will IMO see Physiomics valued at hundreds of millions i.e. multiples of 100p as peers understand its unique specialist history in developing Virtual Tumour cancer model for years with some of the best partners around ICR, CRUK, Oxford Uni, Oxford NHS etc etc | the stigologist | |
22/7/2020 18:07 | Today Physiomics tweeted about the 'Exciting news' from their 'historical client Cyclacel' Now this news is definitely exciting ! (Cyclacel and ICR press released the news on July 13th) What Cyclacel and the renowned ICR (Institute for Cancer Research) are claiming is that they have a EFFECTIVE new PATHWAY to potentially fight Cancer via CDK Inhibition “These exciting new findings revealing fadraciclib’s chemical structure and describing its relevant anti-cancer properties, reflect the highly productive collaboration of ICR with Cyclacel to discover and develop innovative cancer treatments,” said Professor Paul Workman, FMedSci, FRS, study co-author and Chief Executive and President, The Institute of Cancer Research, London, UK. “As a potent and selective inhibitor of CDK2 and CDK9, we believe our cumulative findings to-date support fadraciclib’s ability to address key cancer pathways in solid tumors and leukaemias, indicating its potential as a new targeted anti-cancer therapy.” Why is this significant for Physiomics ? Physiomics have a long history of working with both Cyclacel and the ICR on CDK Inhibitors Several resources on Physiomics website attest to that work So one potential area of interest for Physiomics is that other Pharmas/Biotechs who now want to model either their own CDK pathway drugs or use their existing drugs in combination with CDK Inhibitors may want to come to Physiomics to assist in Modelling and Simulation of those drugs and any future Clinical Trial BUT could there be a second potential area Physiomics benefit from ? Namely from any milestones or royalties from success of Cyclacel drugs based on their work together ? | the stigologist | |
22/7/2020 17:20 | Bones echoing Stigs comment GREAT POST. Nothing has changed the company is still way undervalued BUT we did see how quickly this can rise from 10p. Long term holders will not be put off by daily volatility. Lets wait for the next announcement that will surely follow. | ant15 | |
22/7/2020 16:58 | Is that it then? | divmad |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions